Skip to main navigation
  • •
  • Follow Us:
  • Facebook
  • Twitter
  • Linkedin
  • Grant Portal
Catalystpharma.com
  • About Catalyst
    • History
    • Management
    • Board Of Directors
    • Events and Presentations
    • Careers
    • Contact Us
  • Patient Focus
    • Patient Stories
      • LEMS Stories
    • Disease Information
      • LEMS
      • MuSK-MG
      • Duchenne Muscular Dystrophy (DMD)
    • Patient Resources
      • Organizations
      • Event Calendar
      • Patient Engagement
  • Research & Pipeline
    • Roadmap To Success (Strategy)
    • Pipeline (clinical)
      • LEMS Clinical
    • Business Development
    • Healthcare Professional Outreach
    • Clinical Trials
  • Products
    • APPROVED PRODUCTS
  • ESG Responsibility
    • Corporate Giving
    • Investigator Sponsored Research
    • ESG Report
      • ESG SASB DISCLOSURE
  • Investors
    • Press Releases
    • Events & Presentations
    • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Board of Directors
      • Management
      • Committee Composition
      • Board Diversity Matrix
      • Contact the Board
    • Stock Information
      • Stock Information
      • Historic Stock Lookup
    • Annual Report and Proxy
    • Analyst Coverage
    • Email Alerts
Select Page

Investors

  • Press Releases
  • Events & Presentations
  • SEC Filings
  • Corporate Governance
    • Board of Directors
    • Management
    • Committee Composition
    • Board Diversity Matrix
    • Contact the Board
  • Stock Information
  • Annual Report and Proxy
  • Analyst Coverage
  • Email Alerts

Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases.  With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases.  Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS.  Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.

Events & Presentations

Nov 9, 2023 at 8:30 AM EST
Catalyst Pharmaceuticals Third Quarter 2023 Financial Results Conference Call Webcast
Sep 26, 2023 at 11:05 AM EDT
2023 Cantor Global Healthcare Conference
More

Latest Press Releases

Dec 05, 2023
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
Dec 04, 2023
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions
More

Stock Quote

Change
Volume
52 Week High
52 Week Low
Dec 8, 2023 4:06 PM EST
More
Best Companies
  • Email Alerts
  • RSS
  • Print page
  • Search
Catalyst Pharmaceuticals logo
  • ABOUT CATALYST
  • PATIENT FOCUS
  • RESPONSIBILITY
  • RESEARCH & PIPELINE
  • EVENTS & PRESENTATIONS
  • CAREERS
  • CONTACT US
  • CLINICAL TRIALS
CONTACT
(305) 420-3200
Email Us
Investors
 

FOLLOW US:

facebook twitter linkedin
© 2020 Catalyst Pharmaceuticals, Inc. All Rights Reserved. 19CRP0211(3) November 2019 | Privacy Policy | Accessibility Statement